Alzheon Stock

alzheon.comHealthcare / BioTech & PharmaFounded: 2013Funding to Date: $90.97MM

Alzheon is a biopharmaceutical company striving to develop treatments designed for patients with Alzheimer’s Disease and other neurodegenerative disorders. Alzheon was founded in 2013 and is headquartered in Framingham, MA. Their leading candidate, ALZ-801, is an oral anti-amyloid treatment aimed at slowing or preventing Alzheimer’s disease, particularly in patients with specific genetic markers.

Register To Buy and Sell Shares

For more details on financing and valuation for Alzheon, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Alzheon’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Alzheon.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Alzheon investors also invested in these private companies

Thornapple River Capital
The National Institute on Aging (NIA)
HCL Capital
Aptorum Group


Management Team

Martin Tolar MD Ph.D
Founder, President & Chief Executive Officer
John Hey Ph.D
Chief Scientific Officer
Susan Abushakra MD
Chief Medical Officer
Aidan Power
Chief Development Officer
Kenneth Mace
Chief Financial Officer
Glenn Pauly
Chief Commercial Officer
Adem Albayrak
Chief of Staff

Frequently Asked Questions About Alzheon’s Stock

Can you buy Alzheon’s stock?
Alzheon is not publicly traded on NYSE or NASDAQ in the U.S. To buy Alzheon’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Alzheon’s stock?
Yes, you can sell stock of a private company like Alzheon. Forge can help you sell your Alzheon stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Alzheon’s stock price?
Alzheon is a privately held company and therefore does not have a public stock price. However, you may access Alzheon’s private market stock price with Forge Data.
What is Alzheon’s stock ticker symbol?
Alzheon does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing
In a series E funding round Alzheon raised $100 million.
Alzheon bolsters executive staff in preparation for launch of new Alzheimer’s drug
Alzheon, a biopharmaceutical company, has promoted Glenn Pauly to chief commercial officer and appointed two new vice presidents ahead of the commercial launch of a new investigational drug, ALZ-801, which could potentially slow or prevent early Alzheimer’s disease. The company anticipates a successful commercial launch in 2025.
Updated on: Jun 16, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.